[1] Pitzalis C, Jones GW, Bombardieri M, et al.Ectopic lymphoid-like structures in infection, cancer and autoimmunity[J]. Nat Rev Immunol, 2014, 14(7):447-462. [2] Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer[J]. Science, 2022, 375(6576): eabf9419. [3] Dieu-Nosjean MC, Goc J, Giraldo NA, et al.Tertiary lymphoid structures in cancer and beyond[J]. Trends Immunol, 2014, 35(11): 571-580. [4] Fridman WH, Meylan M, Pupier G, et al.Tertiary lymphoid structures and B cells: an intratumoral immunity cycle[J]. Immunity, 2023, 56(10): 2254-2269. [5] Sautès-Fridman C, Petitprez F, Calderaro J, et al.Tertiary lymphoid structures in the era of cancer immunotherapy[J]. Nat Rev Cancer, 2019, 19(6): 307-325. [6] Helmink BA, Reddy SM, Gao J, et al.B cells and tertiary lymphoid structures promote immunotherapy response[J]. Nature, 2020, 577(7791): 549-555. [7] Wang B, Liu J, Han Y, et al.The presence of tertiary lymphoid structures provides new insight into the clinicopathological features and prognosis of patients with breast cancer[J]. Front Immunol, 2022, 13: 868155. [8] Sun X, Liu W, Sun L, et al.Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer[J]. J Immunother Cancer, 2022, 10(11): e005531. [9] Zhang C, Wang XY, Zuo JL, et al.Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases[J]. J Immunother Cancer, 2023, 11(2): e006425. [10] El-Naggar AK, Chan JKC, Grandis JR, et al.World Health Organization classification of head and neck tumours[M]. Lyon: IARC Press, 2017. [11] Liu Z, Meng X, Zhang Y, et al.FUT8-mediated aberrant N-glycosylation of SEMA7A promotes head and neck squamous cell carcinoma progression[J]. Int J Oral Sci, 2024, 16(1): 26. [12] Li Q, Liu X, Wang D, et al.Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma[J]. Int J Oral Sci, 2020, 12(1): 24. [13] Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes[J]. Cell, 2023, 186(6): 1127-1143.e18. [14] Fridman WH, Meylan M, Petitprez F, et al.B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome[J]. Nat Rev Clin Oncol, 2022, 19(7): 441-457. [15] Burtness B, Harrington KJ, Greil R, et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928. [16] Xu SM, Shi CJ, Xia RH, et al.Analysis of immunological characteristics and genomic alterations in HPV-positive oropharyngeal squamous cell carcinoma based on PD-L1 expression[J]. Front Immunol, 2022, 12: 798424. [17] Li H, Zhu SW, Zhou JJ, et al.Tertiary lymphoid structure raises survival and immunotherapy in HPV- HNSCC[J]. J Dent Res, 2023, 102(6): 678-688. [18] Seki M, Sano T, Saito E, et al.Tertiary lymphoid structures in tongue cancer: association with clinicopathological parameters, preoperative S-1 chemotherapy response, and prognosis[J]. J Oral Pathol Med, 2024, 53(2): 124-132. [19] Hayashi Y, Makino T, Sato E, et al.Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors[J]. Br J Cancer, 2023, 128(12): 2175-2185. [20] He W, Zhang D, Liu H, et al.The high level of tertiary lymphoid structure is correlated with superior survival in patients with advanced gastric cancer[J]. Front Oncol, 2020, 10: 980. [21] Xu W, Lu J, Liu WR, et al.Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma[J]. J Immunother Cancer, 2023, 11(12): e006667. [22] Chow LQM.Head and neck cancer[J]. N Engl J Med, 2020, 382(1): 60-72. [23] Burtness B, Rischin D, Greil R, et al.Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score[J]. J Clin Oncol, 2022, 40(21): 2321-2332. [24] Kaur A, Kuchta K, Watkin W, et al.Programmed death ligand-1 combined positive score concordance and interrater reliability in primary tumors and synchronous lymph node metastases in resected cases of p16+ oropharyngeal squamous cell carcinoma[J]. Arch Pathol Lab Med, 2023, 147(4): 442-450. [25] Schoenfeld JD, Hanna GJ, Jo VY, et al.Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1563-1570. [26] Ferris RL, Spanos WC, Leidner R, et al.Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial[J]. J Immunother Cancer, 2021, 9(6): e002568. [27] Hashimoto M, Ramalingam SS, Ahmed R.Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy[J]. Trends Cancer, 2023, 10(4): 332-346. [28] Lechner A, Schlößer HA, Thelen M, et al.Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma[J]. Oncoimmunology, 2019, 8(3): 1535293. [29] Johansson-Percival A, He B, Li ZJ, et al.De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors[J]. Nat Immunol, 2017, 18(11): 1207-1217. [30] Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation[J]. Sci Transl Med, 2017, 9(385): eaak9679. [31] Esparcia-Pinedo L, Romero-Laorden N, Alfranca A.Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer[J]. Front Immunol, 2023, 14: 1231315. |